Lutetium Lu 177 dotatate: all 46 studies that test it

Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.RecruitingNCT07150546Phase 1
• A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETsRecruitingNCT07057622Phase 3
• Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/2
• 177Lu-DOTATATE Modified Delivery Based on Individualized DosimetryRecruitingNCT06395402Phase 2
• 177Lu-DOTATATE for Recurrent MeningiomaRecruitingNCT06326190Phase 2
• Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed IndicationsNot yet recruitingNCT06121271Phase 2
• Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT06016855Phase 4
• Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingNCT05773274Phase 2
• Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsRecruitingNCT05691465Phase 2
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingNCT05687123Phase 1
• Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell CancerRecruitingNCT05583708Phase 2
• Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsRecruitingNCT05278208Phase 1/2
• Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NETRecruitingNCT04954820Phase 2
• 177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk NeuroblastomaRecruitingNCT04903899Phase 2
• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsRecruitingNCT04665739Phase 2
• 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast CancerRecruitingNCT04529044Phase 2
• Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation TherapyRecruitingNCT04082520Phase 2
• Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine TumorsActive, not recruitingNCT04234568Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETActive, not recruitingNCT03972488Phase 3Results posted
• A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursCompletedNCT01578239Phase 3Results posted
• NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Active, not recruitingNCT06379217Phase 1
• Using Novel Imaging to More Safely Treat Neuroendocrine TumorsCompletedNCT06122610Phase 1
• Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver MetastasesTerminatedNCT05987176Phase 2
• Biomarker Identification of Radionuclide Therapy-induced Radiation ResponsesStatus unknownNCT05513469Not applicable
• Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET TrialActive, not recruitingNCT05247905Phase 2
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabActive, not recruitingNCT05142696Phase 1/2
• Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsActive, not recruitingNCT04750954Phase 1
• Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive SurgeryActive, not recruitingNCT04609592Phase 1
• Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the LiverActive, not recruitingNCT04544098Early Phase 1
• A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine TumoursStatus unknownNCT04525638Phase 2
• Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNETCompletedNCT04385992Phase 2
• 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive TumoursCompletedNCT04375267Phase 1
• Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine CancersWithdrawnNCT04106843Phase 2
• Carcinoid Heart Disease and Peptide Receptor Radiotargetted TherapyStatus unknownNCT04039516Phase 2
• Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR OverexpressionStatus unknownNCT04029428Phase 2
• Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk MeningiomaActive, not recruitingNCT03971461Phase 2
• Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and AdolescentsWithdrawnNCT03923257Phase 1/2
• Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver MetastasesCompletedNCT03590119Phase 2/3
• Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine TumorsStatus unknownNCT03478358Phase 1
• Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine TumorsTerminatedNCT02489604Phase 2
• Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase IICompletedNCT02230176Phase 2
• A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine TumoursSuspendedNCT01876771Phase 2
• Randomized Phase III of PRRT Versus InterferonWithdrawnNCT01860742Phase 3
• 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETsCompletedNCT01842165Phase 3
• A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine TumorsCompletedNCT01456078Phase 2
• 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine NeoplasmsCompletedNCT01237457Phase 2

← Lutetium Lu 177 dotatate overview